Magnetic resonance imaging and clinical outcome in patients with symptomatic carotid artery stenosis after carotid artery revascularization

Rafał Badacz1, Anna Kabłak-Ziembicka1, Małgorzata Urbańczyk-Zawadzka1, Robert P. Banyś2, Piotr Musiałek1, Piotr Odrowąż-Pieniążek1,3, Mariusz Trystuła4, Jan Ścigalski2, Krzysztof Żmudka1, Tadeusz Przewłocki1,3

1Department of Interventional Cardiology, Jagiellonian University Medical College, the John Paul II Hospital, Krakow, Poland
2Department of Radiology and Diagnostic Imaging, the John Paul II Hospital, Krakow, Poland
3Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, the John Paul II Hospital, Krakow, Poland
4Department of Vascular and Endovascular Surgery, the John Paul II Hospital, Krakow, Poland
5Department of Neurology and Stroke Unit, the Rydygier Hospital, Krakow, Poland

Abstract

Introduction: About 30% of patients with carotid artery stenosis (CAS) develop dementia after a cerebral ischemic event (CIE), and 20–50% suffer from CIE recurrence during 6 months. Carotid artery revascularization (CAR) may prevent CIE recurrence, at the cost of new microembolic lesions (MES). The impact of CAR on cognitive function is debatable.

Aim: To assess functional and cognitive outcome, cerebral flow on transcranial Doppler (TCD) and brain magnetic resonance imaging (MRI) in patients with symptomatic CAS referred for CAR.

Material and methods: Twenty-two patients (aged 69.0 ± 7.2 y.o., 15 male) with recent CIE (21.9 ± 20.9 days to CAR) related to CAS of mean 89.8 ± 3.9% lumen reduction were prospectively evaluated with TCD, diffusion and perfusion MRI, Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), modified Rankin Scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS) 24 h before, at 24–48 h and 1 month following CAR.

Results: New MES were found in 11 (50%) subjects following CAR. CAR resulted in a significant increase of cerebral flow velocity in the middle and anterior cerebral arteries (p < 0.002 and p = 0.003; respectively) and cerebral perfusion measured by time to peak (TTP) and mean transit time (MTT) (p = 0.0009 and p = 0.0002; respectively). Neurologic tests showed improvement in NIHSS (2.4 ± 1.6 to 1.5 ± 1.2, p = 0.003), mRS (from 1.3 ± 0.9 to 0.7 ± 0.9, p = 0.005), and MMSE (26.7 ± 2.2 to 27.6 ± 2.3, p = 0.019) at 1 month, while similar MoCA scores were observed before and 1 month after CAR (23.4 ± 3.3 vs. 24.1 ± 3.7, p = 0.136).

Conclusions: Improvement of cerebral flow and perfusion and functional outcome, as well as at least no cognitive decline, is observed after CAR for symptomatic CAS.

Key words: symptomatic carotid artery stenosis, microembolic ischemic lesions, cerebral perfusion, magnetic resonance, transcranial color-coded Doppler, cognitive assessment.

Introduction

Carotid artery stenosis (CAS) plays an important role in cerebral ischemic event (CIE) incidence, e.g. ischemic stroke (IS) or transient ischemic accident (TIA), accounting for about 14% of all ISs according to the Oxford Vascular Study [1]. About one third of patients develop cognitive dementia following CIE [2], while 20–50% of subjects with symptomatic CAS suffer from CIE recurrence during 6 months [2–4]. Furthermore, CAS frequently co-exists with arterial occlusive disease in other vital territories, which also impacts the cardiovascular prognosis in this group of subjects [5, 6].

According to current guidelines prompt carotid artery revascularization (CAR) is recommended in patients with CAS exceeding 50% lumen reduction, preferably within 2 weeks following CIE [7, 8]. This approach is associated with 33% recurrent CIE risk reduction for inter-
ventional treatment as compared to the optimal medical approach [1].

Cerebral perfusion improvement seems a reasonable consequence of the restored cerebral flow after CAR, and this theoretically should be associated with an improvement in cognitive and functional status. Indeed, some researchers emphasize the role of cerebral perfusion improvement following CAR as a predictor of cognitive outcome [9].

However, the procedure either with carotid artery stenting (PTA) or carotid endarterectomy (CEA) may be potentially associated with further cognitive function decline, which may be attributed to new acute microembolic lesions (MES), noted on brain diffusion-weighted magnetic resonance imaging (DWI-MRI) or periprocedural transcranial color-coded duplex Doppler (TCD) monitoring [10–12]. On the other hand, some studies do not support the relationship between MES and cognitive function decline [9, 13]. Moreover, according to some studies there is no association between periprocedural MES and cerebral perfusion [14–16].

**Aim**

This present study, covering a variety of aspects concerning the outcome of CAR either by CEA or by PTA, was aimed to assess functional and cognitive outcome, with regard to cerebral flow on TCD and DWI-MRI in patients with recently symptomatic CAS.

**Material and methods**

The study included 22 consecutive patients, (mean age: 69 ±7.2 y.o., 15 male) with recent CIE (21.9 ±20.9 days to CAR, range: 5–89) defined as first IS or TIA, related to severe CAS (mean stenosis degree: 89.8 ±3.9%, range: 80–99%), who were admitted to the Vascular and Endovascular Surgery Department between September 2015 and January 2017 with the aim of CAR.

The eligibility criteria were as follows: first CIE, unilateral, symptomatic CAS > 70%, measured with carotid Duplex ultrasound, using the NASCET criteria, history of IS or TIA within 60 days prior to CAR.

The exclusion criteria were as follows: history of former CIE, patients with bilateral CAS, including contralateral carotid artery occlusion, known other potential causes of CIE (atrial fibrillation, patent foramen ovale, cerebral artery aneurysms/malformations), non-diagnostic temporal window for TCD, contraindications for MRI, known prior advanced dementia with Mini-Mental State Examination (MMSE) score below 20 and Montreal Cognitive Assessment Scale (MoCA) score below 14.

Each patient signed an informed consent form before the revascularization procedure. The study was performed according to the institutional bioethics committee and was performed in accordance with the Declaration of Helsinki.

At baseline, demographic data, presented symptoms, medical characteristics as well as cardiovascular risk factors (such as hypertension, hypercholesterolemia, diabetes mellitus, or active smoking) were collected from each patient. The obtained information included age, gender, history of coronary artery disease (CAD), myocardial infarction (MI), history of coronary revascularization (both PCI and CABG), as well as interventions within peripheral arteries.

The qualifying IS or TIA was based on the consultant neurologist’s opinion, and sourced from medical documentation and obtained brain imaging either with computed tomography (CT) or MRI.

**Internal carotid artery revascularization**

The patients admitted to the department were referred for PTA or CEA depending on the Vascular Team multidisciplinary decision, including the consultant neurologist. Carotid artery angiography was performed before CAR with the measurement of internal carotid artery lumen reduction using quantitative assessment (Siemens, Coroscop, Enlagent, Germany). The PTA was performed according to Tailored-CAS criteria, with a proximal or distal neuroprotection system in patients treated with dual antiplatelet therapy [17]. Stent and neuroprotection system selection was made according to degree of stenosis, plaque morphology and collateral cerebral flow [17]. The CEA was performed on a single antiplatelet agent and periprocedural heparin. The procedure technique choice was left at the discretion of the operating surgeon. All CEAs were performed with eversion technique and periprocedural shunt.

**Carotid ultrasonography**

The severity of CAS was assessed by high-resolution B-mode, color Doppler and pulse Doppler ultrasonography of extracranial arteries and was performed with an ultrasound machine (Toshiba Apio TUS-A300; Saronno, Italy) fitted with a linear-array 7.5 MHz transducer. Patients were examined in a supine position with the head tilted backwards. In compliance with the Carpenter criteria [18], the grade of stenosis in carotid arteries was assessed by measuring the increase in the peak systolic velocity (PSV) > 2.1 m/s and the end-diastolic velocity (EDV) > 0.7 m/s. Carotid plaque morphology was classified in accordance with Gray-Weale criteria [19], in brief: four plaque types were defined based on their degree of echolucency assessed in B-mode view: type 1: predominantly echolucent, type 2: intermediate echolucent lesions with small areas of echogenicity, type 3: intermediate echogenic lesions with small areas of echolucency, type 4: uniformly echogenic lesions. Furthermore, the plaque surface was described as either smooth, irregular or ulcerated.

**Transcranial color-coded duplex Doppler**

Following the carotid ultrasound, every patient had a TCD examination performed through the temporal
Advancements in Interventional Cardiology 2017; 13, 3 (49)

The examination of intracranial arteries was performed with a Toshiba Aplio TUS-A300 (Saronno, Italy) machine fitted with a sector-array 1.5–2.5 MHz transducer. TCD examination included measurements of PSV and EDV in the first segments of cerebral arteries within the circle of Willis: ipsilateral to stenosed ICA in middle (MCA), and anterior (ACA) cerebral arteries, as well as contralateral MCA and ACA.

Furthermore, the flow directions and functions of anterior (ACoA) and posterior (PCoA) communicating arteries were assessed. The ACoA was assessed as present when the same flow directions in the ipsilateral MCA and ACA were observed. PCoA was assessed as present when the blood flow between the trifurcation and ipsilateral posterior cerebral artery (P1/P2 segment) was recorded on TCD [20]. All scans were obtained by the same experienced sonographer who had no prior knowledge of the subjects’ clinical and angiographic characteristics.

Both carotid ultrasound and TCD were performed 1 day prior to CAR, at 24–48 h after CAR and 4 weeks following CAR.

### Magnetic Resonance Imaging

To assess cerebral perfusion, magnetic resonance scans were obtained 1 day prior to CAR, at 24–48 h after CAR and 4 weeks following CAR.

The imaging was performed with a 1.5 T scanner (Magnetom Sonata Maestro Class, Erlangen, Germany), using a dedicated 8-element head coil. The protocol covered the DWI as well as perfusion-weighted imaging (PWI) with cerebral blood volume (CBV), cerebral blood flow (CBF), time to peak (TTP), and mean transit time (MTT), calculated upon acquired images. The scanning protocols included T1-weighted images, T2-weighted images and FLAIR images. Dynamic susceptibility contrast (DSC) MRI is also known as PWI.

On DWI imaging 24–48 h after CAR any new detectable lesions within both hemispheres, not visualized in the study prior to CAR, were considered as MES. The total number of lesions and maximal diameter were calculated manually by a qualified radiologist.

The PWI data were acquired using T2*-weighted imaging by a gradient echo-planar sequence with the first passage of contrast bolus in brain tissues, after intravenous injection of a standard dose of 0.05 mmol/kg body weight of gadolinium-based contrast agent with the flow of 5 ml/s followed by a bolus of 20 ml saline (0.9% NaCl) with the same flow (5 ml/s) using an automatic power injector. During the first pass of gadolinium-based contrast agent it is confined in the vasculature and produces local magnetic field gradients that induce a decrease in the signal of T2*-weighted images (susceptibility effects). These susceptibility effects are seen as a transient signal loss in the tissue of interest on T2*-weighted imaging.

Using commercially available software, various functional parameters and maps of TTP and MTT were calculated from the time-signal intensity curves measured in each pixel. Maps can be interpreted visually or quantitatively by calculating the relative values. The range of values of each perfusion parameter is demarcated by a color scale, usually with the color red indicating the highest values and blue representing the lowest values.

The regions of interest were set manually within the area of MCA parallel in both hemispheres as well as within the venous sinus. The assessment was made before CAR, 24–48 h after CAR and after 4 weeks of follow-up for the ipsilateral hemisphere. The mean values of MTT and TTP were calculated for each patient separately in each study.

### Cognitive Function

Cognitive function of the study participants was assessed with Montreal Cognitive Assessment (MoCA) [21, 22] and Mini Mental State Examination (MMSE) [23] scales, prior to CAR, 24–48 h after CAR and after 1-month of follow-up. The exclusion criteria were the cut-off score values equal to or below 20 and 14 for MMSE and MoCA, respectively, as suggesting severe dementia.

### Functional Status

Functional outcome was estimated using the modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) at 24 h before CAR, at 24–48 h after and at 1 month following CAR [24, 25].

### Statistical Analysis

Continuous variables are presented as mean ± one SD, categorical variables are expressed as frequencies and percentages. Means of analyzed parameters across groups were tested with the analysis of variance (ANOVA) test, and frequencies were compared by the χ² test for independence. The non-parametric Mann-Whitney U test was used to determine differences in peak-systolic flow velocities recorded in the corresponding cerebral arteries among the studied group of patients as well as the differences in neuropsychological and functional tests’ outcomes. The non-parametric Wilcoxon test for dependent samples was performed to assess the differences in PWI parameters: MTT and TTP in studies performed before and after CAR, the associations between PWI parameter changes and new MES following CAR, as well as the change in neuropsychological tests’ outcomes before and after CAR. The correlation between brain PWI assessment (TTP and MTT values) on MRI and cerebral flow on TCD, as well as the correlation between appearance of new, acute MES following CAR and improvement of PWI parameters and neurocognitive test results, was calculated with the non-parametric Spearman’s rank-order test. Statistical analyses were performed with Statis-
tica 12.0 software. Statistical significance was assumed at \( p < 0.05 \).

**Results**

Baseline characteristics of study participants are shown in Table I.

Upon assessment of carotid plaque morphology, the majority of plaques observed in study participants were considered high risk (type I and II), as evidenced by ultrasonography and post-CAR histological assessment of plaques (Table I).

The PTA was performed in 17 (77.3%), CEA in 5 (22.7%) subjects (Table II). Periprocedural 30-day complications occurred in 3 (13.6%) subjects, including 2 (9.0%) CIE (NIHSS 5, mRS 3 and NIHSS 2, mRS 1 respectively) after PTA observed within 24 h following CAR, the first one presenting with moderate motoric aphasia, which diminished significantly on examination after 1 month of follow-up, the second one with mild left upper limb paresis, as well as atrial fibrillation in 1 patient after CEA with no further clinical consequences. No periprocedural deaths, MI, major IS or TIA were noted.

**Diffusion-weighted magnetic resonance imaging**

Acute and subacute multiple cerebral ischemic lesions were observed on DWI-MRI in all subjects before CAR (mean lesion size of 17 ±14.9 mm, range: 4–58 mm). Two patients suffered from periprocedural CIE. One had multiple ischemic lesions of maximum 24 mm in the left hemisphere with moderate motoric aphasia (NIHSS = 5). At 4 weeks following CAR, the lesion decreased to 19 mm. The second one had isolated ischemic lesions of maximum 69 mm with mild left upper limb paresis (NIHSS = 2).

After CAR, DWI-MRI post-procedurally was contraindicated in 1 subject due to placement of the metal sternal clips.

In the remaining 18 uncomplicated patients, new MES were found in 9 (47.4%) on 24–48 h DWI-MRI examination following CAR (Table III). In these subjects, the mean number of MES was 3.0 ±2.4 (range: 1–9), with the mean lesion size of 4.3 ±2.2 mm (range: 3–8 mm). Of those, in 2 (22.2%) patients MES resolved completely, while in 6 (66.7%) patients MES decreased on DWI-MRI at 1 month after CAR.

**Table I.** Clinical characteristics of study participants

| Parameter                          | Value            |
|-----------------------------------|------------------|
| Number of patients                | 22               |
| Age                               | 69.0 ±7.2, range: 56–81 |
| Male gender                       | 15 (68.2%)       |
| Hypertension                      | 22 (100%)        |
| Diabetes mellitus                 | 6 (27.3%)        |
| Hyperlipidemia                    | 21 (95.5%)       |
| Cigarette smoking – current or former | 7 (31.8%)     |
| Coronary artery disease*          | 13 (59.1%)       |
| History of myocardial infarction  | 1 (4.5%)         |
| History of PCI                    | 3 (13.6%)        |
| History of CABG                   | 1 (4.5%)         |
| Peripheral arterial disease       | 6 (27.3%)        |
| Grade of ICAS before CAR**        | 89.8 ±3.9%, range: 80–99% |
| String stenosis                   | 7 (31.8%)        |
| Plaque morphology:                |                  |
| Type 1: Predominantly echolucent  | 5 (22.7%)        |
| Type 2: Intermediate echolucent   | 10 (45.5%)       |
| Type 3: Intermediate echogenic    | 5 (22.7%)        |
| Type 4: Uniformly echogenic       | 2 (9.1%)         |
| Ulceration                        | 14 (63.6%)       |
| Histopathological assessment:     |                  |
| Thrombotic                        | 4 (18.2%)        |
| Lipid rich                        | 7 (31.8%)        |
| Fibrotic                          | 4 (18.2%)        |
| Heterogeneous                     | 5 (22.7%)        |
| Calcified                         | 2 (9.1%)         |

*Significant coronary artery stenosis exceeding 50% lumen reduction on coronary angiography, **according to NASCET criteria.

**Table II.** Details of CAR procedure techniques performed in presented subjects

| Parameter                  | Value |
|----------------------------|-------|
| CAR                        | 22    |
| Carotid artery stenting    | 17 (77.3%) |
| Neuroprotection system:     |       |
| Distal                     | 9 (52.9%) |
| Proximal                   | 8 (47.1%) |
| Stent type:                |       |
| C-Guard                    | 5 (29.4%) |
| RoadSaver                  | 5 (29.4%) |
| Carotid Wallstent          | 4 (23.5%) |
| Cristallo                  | 2 (11.8%) |
| Xact                       | 1 (5.9%)  |
| Direct stenting            | 4 (23.5%) |
| Predilatation              | 13 (76.5%) |
| CEA                        | 5 (22.7%) |
| Eversion                   | 5 (100%)  |
| Shunt                      | 5 (100%)  |

CAR – carotid artery revascularization, CEA – carotid endarterectomy.
Thus, MES occurred in 1 out of 5 (20%) patients after CEA, and 8 out of 14 (57%) subjects after PTA. The mean diameter of MES after CEA was 4 mm and after PTA 3.9 ±2.3, range: 1–8 mm.

After 1 month, among all patients cerebral ischemic lesions persisted in 6 (27.3%), resolved in 3 (13.6%), decreased in 12 (54.5%) and progressed in 1 (4.5%) patient.

**Perfusion-weighted imaging magnetic resonance imaging**

Prior to CAR, perfusion in the hemisphere ipsilateral to CAS was significantly impaired, as compared to the contralateral hemisphere, as evidenced by longer TTP (35.5 ±4.3 vs. 35.0 ±4.5 s, p = 0.042). As for MTT, the results failed to reach statistical significance (22.4 ±3.5 vs. 21.3 ±4.3 s, p = 0.155).

At 1 month following CAR, PWI-MRI showed improvement of cerebral perfusion in the hemisphere supplied by the revascularized ICA, resulting in similar TTP and MTT parameters in both hemispheres (32.5 ±3.8 vs. 32.7 ±3.6 s; p = 0.783 and 17.9 ±3.3 vs. 18.7 ±3.7 s; p = 0.055 respectively).

At 1 month, there was a significant improvement in cerebral PWI in all subjects, expressed as shortening of passage times for TTP (from mean 36.1 ±4.2 to 32.6 ±3.9; p = 0.0009, range: –1.5 to –11.9 s) and for MTT (from mean 22.8 ±3.4 to 17.8 ±3.4; p = 0.0002; range: –1.5 to –10.8 s), as compared to pre-procedural values. There was no statistical difference in brain perfusion improvement measured by MTT and TTP in patients with and without new, acute MES in brain DWI (Table III).

**Transcranial color-coded duplex Doppler**

Both 24–48 h after CAR and at 1 month following CAR, there was a significant increase of cerebral flow velocity at the site of the procedure as compared to the examination performed prior to revascularization: in the MCA from 75 ±19.7 to 117 ±33.8 and to 98 ±22.7 cm/s, p = 0.001, respectively and in the ACA from 76 ±25.9 to 101 ±30.0 and to 87 ±20.2 cm/s, p = 0.021; respectively, Table IV.

The flow increase seen on TCD was not correlated with cerebral perfusion increase seen on PWI-MRI. The difference between post-procedural velocities and pre-procedural velocities in the MCA was not correlated with change in either TTP or MTT, both at 24–48 h and 1 month following CAR (p = NS).

**Functional and cognitive outcome**

Improvement of cognitive function was found in 16 (72.7%) by MMSE and in 14 (63.6%) subjects by MoCA at 1 month following CAR. MMSE scores were: 26.7 ±2.2, 27.4 ±2.0 and 27.6 ±2.3 before, at 24–48 h and at 4 weeks following CAR, respectively, meaning that there was a significant improvement of cognitive function 4 weeks after CAR as compared to pre-procedural assessment (p = 0.019).

The MoCA scores were 23.4 ±3.3, 23.9 ±3.1 and 24.1 ±3.7 before, at 24–48 h and at 4 weeks following CAR respectively, with no significant difference between the respective examinations (p = 0.136), which means no cognitive decline assessed by MoCA, despite the lack of statistically significant improvement. There was no correlation between the improvement of cerebral perfusion and improvement of MMSE and MoCA results.

Functional outcome, measured with NIHSS and mRS, significantly improved 4 weeks after CAR from 2.3 ±1.6 to 1.4 ±1.2 (p = 0.012) and from 1.2 ±0.9 to 0.7 ±0.9 (p = 0.012), respectively (Table IV). In 7 patients NIHSS and in 9 patients mRS remained unchanged. New MES were not associated with cognitive function outcome or cerebral perfusion at 1 month after CAR as compared to pre-procedural values (Table III).

| Variable | Subjects with acute MES after CAR (n = 9) | Subjects without acute MES after CAR (n = 10) | P-value |
|----------|------------------------------------------|---------------------------------------------|---------|
| NIHSS change before vs. 1 month after CAR | –0.8 ±0.9 | –1.1 ±1.0 | 0.505 |
| mRS change before vs. 1 month after CAR | –0.4 ±0.5 | –0.6 ±0.5 | 0.450 |
| MMSE change before vs. 1 month after CAR | 1.0 ±1.5 | 0.9 ±1.9 | 0.902 |
| MoCA change before vs. 1 month after CAR | 0.3 ±2.3 | 1.5 ±2.8 | 0.437 |
| TTP change before vs. 1 month after CAR | –3.51 ±2.63 | –3.72 ±4.21 | 0.911 |
| MTT change before vs. 1 month after CAR | –6.35 ±2.51 | –3.42 ±3.11 | 0.112 |

TTP – time to peak, MTT – mean transit time, MMSE – Mini-Mental State Examination, MoCA – Montreal Cognitive Assessment, NIHSS – National Institute of Health Stroke Scale, mRS – modified Rankin Scale.

*One patient had no DWI-MRI after CAR due to sternal metal clips; in 2 patients PTA was complicated by minor IS with new ischemic lesions on brain MRI. Data are presented as the difference between pre-procedural and 1-month follow-up values.
Table IV. Cognitive and functional outcome as well as cerebral perfusion in TCD and brain MRI before, 24–48 h after and 1 month after CAR in patients with symptomatic carotid artery stenosis

| Variable                  | Before CAR | 24–48 h after CAR | After 4-week follow-up | P-value |
|---------------------------|------------|-------------------|------------------------|---------|
| TCD:                      |            |                   |                        |         |
| iMCA PSV [cm/s]           | 75 ±19.7   | 117 ±33.8         | 98 ±22.7               | 0.001   |
| iACA PSV                  | 76 ±25.9   | 101 ±30.0         | 87 ±20.2               | 0.021   |
| cMCA PSV                  | 122 ±34.0  | 119 ±23.8         | 106 ±22.9              | 0.026   |
| cACA PSV                  | 125 ±38.9  | 96 ±22.2          | 88 ±23.9               | 0.005   |
| Functional status:        |            |                   |                        |         |
| NIHSS                     | 2.3 ±1.6   | 2.3 ±1.7          | 1.4 ±1.2               | 0.003   |
| mRS                       | 1.2 ±0.9   | 1.3 ±1.0          | 0.7 ±0.9               | 0.005   |
| Cognitive function:       |            |                   |                        |         |
| MMSE                      | 26.7 ±2.2  | 27.4 ±2.0         | 27.6 ±2.3              | 0.019   |
| MoCA                      | 23.4 ±3.3  | 23.9 ±3.1         | 24.1 ±3.7              | 0.136   |
| PWI:                      |            |                   |                        |         |
| TTP                       | 35.5 ±4.3  | 35.5 ±4.2         | 32.5 ±3.8              | 0.0009  |
| MTT                       | 22.4 ±3.5  | 19.6 ±4.2         | 17.9 ±3.3              | 0.0002  |

TTP – time to peak, MTT – mean transit time, MMSE – Mini-Mental State Examination, MoCA – Montreal Cognitive Assessment, NIHSS – National Institute of Health Stroke Scale, mRS – modified Rankin Scale, TCD – transcranial color-coded duplex Doppler, MCA – middle cerebral artery, ACA – anterior cerebral artery.

Discussion

In this preliminary study concerning a variety of factors that may potentially impact the result of CAR in patients after first in their lifetime CIE, we observed the immediate improvement of cerebral flow in terms of the velocity increase in MCA and ACA in the circle of Willis, and cerebral perfusion, as well as a significantly improved functional outcome in all subjects.

In the light of the CIE recurrence rate as well as high 1-year mortality and disability rate, accounting for up to 50%, 20% and 30–40%, respectively, urgent intervention for CAS seems highly justified [4, 7].

We would like to emphasize several aspects of CIE related to CAS. As evidenced by others, and also observed in the present study, the majority of symptomatic patients have carotid plaque morphology which could be called a vulnerable plaque [19]. In subjects with CIE due to CAS, echolucent plaques accounted for 71% of all plaques identified, ulcerated in 67%. Several studies have already confirmed that hypoechoenic, echolucent carotid plaques increase the risk of CIE in patients with CAS and can be a viable predictor of prevalence of future CIE in those patients [26–29].

Furthermore, the collateral cerebral circulation is less prevalent in recently symptomatic patients as compared to asymptomatic with CAS and was observed in 12 (57.1%) of 21 study participants. These findings are in line with our former study on 371 patients, in which the collateral flow within the circle of Willis as observed by TCD was present in 67% of patients with recent CIE [20]. Similarly, in the preliminary study by Ito et al., on 12 subjects, the presence of the ACoA and PCoA on dynamic magnetic resonance angiography was observed in 42% and 17% of symptomatic patients with CAS > 70%, respectively [30].

Our study demonstrated that cerebral perfusion on PWI-MRI prior to CAR was significantly impaired within the hemisphere supplied by the stenotic ICA. Following CAR, we observed similar PWI parameters in both hemispheres. There are limited data concerning this aspect of CAR in the available literature. Piñero et al. observed significantly increased TTP in all patients prior to PTA in the affected hemisphere in comparison to the contralateral hemisphere (p = 0.007) [31]. Similar to our study, normalization of cerebral perfusion was observed for TTP 1 month after PTA in all patients [31].

What is more, cerebral perfusion improved significantly in both hemispheres, which was expressed by the shortening of TTP and MTT bilaterally. A similar outcome in regard to TTP measured briefly after CAR was noted in most, but not all, patients in the study by Gauvrit et al. [32], as well as Tavares et al. [33] and Wang et al. [34].

After CAR, there was an immediate increase in the flow velocities in the ipsilateral MCA and ACA observed in the TCD study 24–48 h following the procedure, which stabilized in the study after 4 weeks of follow-up. Those findings correspond well with another study on 92 patients, which found a significant PSV increase by 26% in the MCA and by 30% in the ACA measured by TCD 24 h after PTA as compared to examination prior to CAR [35]. These results are also in line with available studies con-
fiercing the improvement of circle of Willis flow by either TCD or MRI examination [36, 37].

In our study, the increase of brain perfusion was followed by the improvement of functional outcome and cognitive functions. Concordantly, in the study by Wang et al. [34] concerning 46 patients treated with CEA, PWI improvement after CAR was correlated with the improvement in MoCA (20.5 ±1.7 vs. 22.0 ±1.5, p = 0.001) with a linear correlation between TTP and MoCA (R = −0.893, p < 0.001). In our study there was a statistically significant improvement in MMSE (26.5 ±2.2 vs. 27.9 ±2.0, p = 0.014), but not in MoCA (23.2 ±3.2, vs. 24.3 ±3.2, p = 0.171). In the only available, preliminary study on 20 patients, concerning the effect of PTA on perfusion and cognitive outcome, the improvement of brain perfusion was a strong predictor of cognitive improvement (p = 0.04) [38].

The inevitable consequence of CAR is MES, which are more evident after PTA as compared to CEA. It is still open for discussion whether, and to what degree, new MES impact cognitive function, functional status and brain perfusion.

In our study, there was no association between new MES in DWI-MRI and cognitive and functional status. The incidence of new MES observed in DWI-MRI 24–48 h after PTA was 7/13 (54%), while after CEA it was 1/5 (20%), which is consistent with the available literature [13–16, 39, 40].

However, despite the fact that 40.9% of our patients had evidence of new MES on DWI-MRI, this finding was not associated with poorer functional and cognitive outcome, and it did not have an impact on the cerebral perfusion improvement. It is worth mentioning that, in our study, MES were small in size. Furthermore, in 15% of subjects, MES resolved after 1 month, while in the remaining 52% they decreased significantly. Similarly, Grunwald et al. reported that the presence of DWI lesions did not affect the neuropsychological change, and PTA itself did not lead to cognitive decline [13]. Those findings suggest that although CAR is associated with the acute procedure-related MES, they do not clearly contribute to cognitive deprivation or dementia [13].

In contrast, in the study by Maggio et al. [15], the lesion incidence on DWI-MRI in patients after PTA was 24% and the incidence of new MES after PTA was associated with a significant decrease of cognitive outcome assessed by MMSE: mean MMSE reduction of −3.1 (95% CI ranging from −5.8 to −0.5) in patients with new MES after CAR, as compared to mean MMSE change of +1.1 (95% CI from −0.3 to +2.5) in the group with no new lesions [15]. Similar findings can be found in the paper by Zhou et al. [16], in which the multivariate regression analysis revealed that MES observed after CAR were associated with memory decline (p = 0.016) and overall cognitive deterioration in MMSE (p = 0.026) [16].

To summarize, our findings, as well as available data, indicate that early revascularization after CIE seems to have a beneficial effect on cerebral perfusion, functional status and cognitive function, despite the fact that the revascularization procedure carries the risk of periprocedural microembolisation.

Conclusions

This preliminary study concerning many aspects of CAR following CIE indicated immediate improvement of cerebral flow seen on TCD and brain perfusion in PWI MRI. However, in our study no correlation was observed between the improvement of brain perfusion in PWI-MRI and cerebral flow in TCD examination. We observed an improvement in cognitive function in about 2/3 of patients, as well as in the functional status in the majority of our patients. Our study also demonstrated no correlation between cognitive function changes and new MES after carotid recanalisation. Larger, preferably multicenter studies are necessary to elucidate the association between cognitive function, functional status and brain perfusion.

Acknowledgments

The study was supported from the Jagiellonian University research grant: K/ZDS/005730.

Conflict of interest

The authors declare no conflict of interest.

References

1. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366: 1773-83.
2. Munsch F, Sagnier S, Asselineau J, et al. Stroke location is an independent predictor of cognitive outcome. Stroke 2016; 47: 66–73.
3. STROKE PREVENTION RESEARCH UNIT, Department of Clinical Neurology OU, Level 6, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU U. Model for predicting the risk of ipsilateral ischaemic stroke in patients with recently symptomatic carotid bifurcation stenosis. Available from: http://www.stroke.ox.ac.uk/model/form1.html
4. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-73.
5. Connolly M, Bligin-Freiert A, Ellingson B, et al. Peripheral vascular disease as remote ischemic preconditioning, for acute stroke. Clin Neurol Neurosurg 2013; 115: 2124-9.
6. Kablak-Ziembicka A, Przewłocki T, Stepień E, et al. Relationship between carotid intima-media thickness, cytokines, atherosclerosis extent and a two-year cardiovascular risk in patients with arteriosclerosis. Kardiol Pol 2011; 69: 1024-31.
7. Tendera M, Abayas V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: doc-
Rafał Badacz et al. MRI and outcomes after carotid artery stenting

ument covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851-906.

8. Brott TG, Halperin JL, Abbara S, et al. 2011ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SNAP/SCAI/SIR/SNIS/SVM/SVS Guideline on the management of patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol 2011; 57: e16-94.

9. Cheng Y, Wang YJ, Yan JG, et al. Effects of carotid artery stenting on cognitive function in patients with mild cognitive impairment and carotid stenosis. Exp Ther Med 2013; 5: 1019-24.

10. Kablak-Ziembicka A, Przewlocki T. Carotid artery stenting drawbacks: microembolic ischemic cerebral lesions – do they matter? J Endovasc Ther 2011; 18: 527-30.

11. Plessers M, Van Herzeele I, Vermassen F, et al. Neurocognitive functioning after carotid revascularization: a systematic review. Cerebrovasc Dis 2014; 4: 132-48.

12. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists’ Collaborative Group. Lancet 1999; 353: 2105-10.

13. Grunwald IQ, Papanagiotou P, Reith W, et al. Influence of carotid artery stenting on cognitive function. Neuroradiology 2010; 52: 61-6.

14. Giossetti B, Battuso R, Irace L, et al. Embolism to the brain during carotid stenting and surgery. Acta Chir Belg 2007; 107: 151-4.

15. Maggio P, Altamura C, Landi D, et al. Diffusion-weighted lesions according to the tailored-CAS algorithm are associated with cognitive impairment. J Neurol Sci 2013; 328: 58-63.

16. Zhou W, Hitchner E, Gillis K, et al. Prospective neurocognitive evaluation of patients undergoing carotid interventions. J Vasc Radiol 2012; 56: 1571-8.

17. Pieniążek P, Tekieli L, Musialek P, et al. Carotid artery stenting according to the tailored-CAS algorithm is associated with a low complication rate at 30 days: data from the TARGET-CAS study. Kardiol Pol 2012; 70: 328-42.

18. Hendrikse J, Hartkamp MI, Hillen B, et al. Collateral ability of the circle of willis in patients with unilateral internal carotid artery occlusion: border zone infarcts and clinical symptoms. Stroke 2001; 32: 2768-73.

19. Grønholdt ML, Nordestgaard BG, Schroeder TV, et al. Ultrasound echolucent carotid plaques predict future strokes. Circulation 2001; 104: 68-73.

20. Musialek P, Tracz W, Tekieli L, et al. Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis. J Clin Neurosurgery 2013; 9: 165-75.

21. Ito K, Sasaki M, Kobayashi M, et al. Noninvasive evaluation of collateral blood flow through circle of willis in cervical carotid stenosis using selective magnetic resonance angiography. J Stroke Cerebrovasc Dis 2014; 23: 1019-23.

22. Gauvrit JY, Delmaire C, Henon H, et al. Diffusion/perfusion-weighted magnetic resonance imaging after carotid angioplasty and stenting. J Neurol Neurosurg Psychiatry 2004; 75: 1060-7.

23. Tavares A, Caldas JG, Castro CC, et al. Changes in perfusion-weighted magnetic resonance imaging after carotid angioplasty with stent. Interv Neuroradiol 2010; 16: 161-9.

24. Wang Q, Zhou M, Zhou Y, et al. Effects of carotid endarterectomy on cerebral perfusion and cognitive function in patients with high grade carotid stenosis: a perfusion weighted magnetic resonance imaging study. Eur J Vasc Endovasc Surg 2015; 50: 5-12.

25. Kablak-Ziembicka A, Przewlocki T, Pieniążek P, et al. Assessment of flow changes in the circle of Willis after stenting for severe internal carotid artery stenosis. J Endovasc Ther 2006; 13: 205-13.

26. Youn SW, Kim HK, Do YR, et al. Haemodynamic alterations in cerebral blood vessels after carotid artery revascularisation: quantitative analysis using 2D phase-contrast MRI. Eur Radiol 2013; 23: 2880-90.

27. Shanker SE, Amin-Hanjani S, Bednarski C, et al. Intracranial blood flow changes after extracranial carotid artery stenting. Neurosurgery 2015; 76: 330-6.

28. Moftakhar R, Turk AS, Niemann DB, et al. Effects of carotid or vertebrobasilar stent placement on cerebral perfusion and cognition. AJNR Am J Neuroradiol 2005; 26: 1772-80.

29. Schnaudigel S, Gröschel K, Pilgram SM, et al. New brain lesions on carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke 2008; 39: 1911-9.

30. Sañin N, Solak A, Genc B, et al. Brain diffusion changes in unilateral carotid artery stenosis with non-shunt endarterectomy: correlation with white matter lesions. Clin Neurol Neurosurg 2015; 133: 24-9.